Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

TDP1 and PARP1 deficiency are cytotoxic to rhabdomyosarcoma cells.

Fam HK, Walton C, Mitra SA, Chowdhury M, Osborne N, Choi K, Sun G, Wong PC, O'Sullivan MJ, Turashvili G, Aparicio S, Triche TJ, Bond M, Pallen CJ, Boerkoel CF.

Mol Cancer Res. 2013 Oct;11(10):1179-92. doi: 10.1158/1541-7786.MCR-12-0575. Epub 2013 Aug 2.

2.

PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage.

Das BB, Huang SY, Murai J, Rehman I, Amé JC, Sengupta S, Das SK, Majumdar P, Zhang H, Biard D, Majumder HK, Schreiber V, Pommier Y.

Nucleic Acids Res. 2014 Apr;42(7):4435-49. doi: 10.1093/nar/gku088. Epub 2014 Feb 3.

3.

Identification of a putative Tdp1 inhibitor (CD00509) by in vitro and cell-based assays.

Dean RA, Fam HK, An J, Choi K, Shimizu Y, Jones SJ, Boerkoel CF, Interthal H, Pfeifer TA.

J Biomol Screen. 2014 Dec;19(10):1372-82. doi: 10.1177/1087057114546551. Epub 2014 Aug 12.

PMID:
25117203
4.

TDP1 deficiency sensitizes human cells to base damage via distinct topoisomerase I and PARP mechanisms with potential applications for cancer therapy.

Alagoz M, Wells OS, El-Khamisy SF.

Nucleic Acids Res. 2014 Mar;42(5):3089-103. doi: 10.1093/nar/gkt1260. Epub 2013 Dec 13.

5.

Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.

Oplustilova L, Wolanin K, Mistrik M, Korinkova G, Simkova D, Bouchal J, Lenobel R, Bartkova J, Lau A, O'Connor MJ, Lukas J, Bartek J.

Cell Cycle. 2012 Oct 15;11(20):3837-50. doi: 10.4161/cc.22026. Epub 2012 Sep 14.

6.

Poly(ADP-ribose)polymerase 1 stimulates the AP-site cleavage activity of tyrosyl-DNA phosphodiesterase 1.

Lebedeva NA, Anarbaev RO, Sukhanova M, Vasil'eva IA, Rechkunova NI, Lavrik OI.

Biosci Rep. 2015 Jun 15;35(4). pii: e00230. doi: 10.1042/BSR20140192.

7.

Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.

Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS.

Cell Cycle. 2011 Apr 15;10(8):1192-9. Epub 2011 Apr 15.

8.

PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells.

Węsierska-Gądek J, Zulehner N, Ferk F, Składanowski A, Komina O, Maurer M.

Biochem Pharmacol. 2012 Nov 15;84(10):1318-31. doi: 10.1016/j.bcp.2012.07.024. Epub 2012 Aug 14.

9.

Role of tyrosyl-DNA phosphodiesterase 1 and inter-players in regulation of tumor cell sensitivity to topoisomerase I inhibition.

Perego P, Cossa G, Tinelli S, Corna E, Carenini N, Gatti L, De Cesare M, Ciusani E, Zunino F, Luison E, Canevari S, Zaffaroni N, Beretta GL.

Biochem Pharmacol. 2012 Jan 1;83(1):27-36. doi: 10.1016/j.bcp.2011.09.021. Epub 2011 Sep 29.

PMID:
21978643
10.

Identification of novel PARP inhibitors using a cell-based TDP1 inhibitory assay in a quantitative high-throughput screening platform.

Murai J, Marchand C, Shahane SA, Sun H, Huang R, Zhang Y, Chergui A, Ji J, Doroshow JH, Jadhav A, Takeda S, Xia M, Pommier Y.

DNA Repair (Amst). 2014 Sep;21:177-82. doi: 10.1016/j.dnarep.2014.03.006. Epub 2014 Apr 29.

11.

Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.

Wiegmans AP, Yap PY, Ward A, Lim YC, Khanna KK.

Mol Cancer Ther. 2015 Oct;14(10):2321-31. doi: 10.1158/1535-7163.MCT-15-0374. Epub 2015 Aug 20.

12.

Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer.

De Summa S, Pinto R, Pilato B, Sambiasi D, Porcelli L, Guida G, Mattioli E, Paradiso A, Merla G, Micale L, De Nittis P, Tommasi S.

Cell Death Dis. 2014 Feb 20;5:e1076. doi: 10.1038/cddis.2014.30.

13.

Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.

Sun Y, Gallacchi D, Zhang EY, Reynolds SB, Robinson L, Malinowska IA, Chiou TT, Pereira AM, Li C, Kwiatkowski DJ, Lee PS, Yu JJ.

Am J Respir Cell Mol Biol. 2014 Dec;51(6):738-49. doi: 10.1165/rcmb.2014-0033OC.

14.

DNA repair and resistance to topoisomerase I inhibitors: mechanisms, biomarkers and therapeutic targets.

Alagoz M, Gilbert DC, El-Khamisy S, Chalmers AJ.

Curr Med Chem. 2012;19(23):3874-85. Review.

PMID:
22788763
15.

Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.

Patel AG, Flatten KS, Schneider PA, Dai NT, McDonald JS, Poirier GG, Kaufmann SH.

J Biol Chem. 2012 Feb 3;287(6):4198-210. doi: 10.1074/jbc.M111.296475. Epub 2011 Dec 12.

16.

SCAN1 mutant Tdp1 accumulates the enzyme--DNA intermediate and causes camptothecin hypersensitivity.

Interthal H, Chen HJ, Kehl-Fie TE, Zotzmann J, Leppard JB, Champoux JJ.

EMBO J. 2005 Jun 15;24(12):2224-33. Epub 2005 May 26.

17.

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.

Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J, Rodríguez O, Calvo MT, Aura C, Díez O, Rubio IT, Pérez J, Rodón J, Cortés J, Ellisen LW, Scaltriti M, Baselga J.

Cancer Discov. 2012 Nov;2(11):1036-47. doi: 10.1158/2159-8290.CD-11-0348. Epub 2012 Aug 22.

18.

Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells.

Gottipati P, Vischioni B, Schultz N, Solomons J, Bryant HE, Djureinovic T, Issaeva N, Sleeth K, Sharma RA, Helleday T.

Cancer Res. 2010 Jul 1;70(13):5389-98. doi: 10.1158/0008-5472.CAN-09-4716. Epub 2010 Jun 15. Erratum in: Cancer Res. 2011 Apr 1;71(7):2803.

19.

Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma.

Gill SJ, Travers J, Pshenichnaya I, Kogera FA, Barthorpe S, Mironenko T, Richardson L, Benes CH, Stratton MR, McDermott U, Jackson SP, Garnett MJ.

PLoS One. 2015 Oct 27;10(10):e0140988. doi: 10.1371/journal.pone.0140988. eCollection 2015.

20.

Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.

Johnson N, Johnson SF, Yao W, Li YC, Choi YE, Bernhardy AJ, Wang Y, Capelletti M, Sarosiek KA, Moreau LA, Chowdhury D, Wickramanayake A, Harrell MI, Liu JF, D'Andrea AD, Miron A, Swisher EM, Shapiro GI.

Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):17041-6. doi: 10.1073/pnas.1305170110. Epub 2013 Oct 1.

Supplemental Content

Support Center